- ►endojournals.org NA Sherry, W Chen, JA Kushner, M Glandt, Q … - Endocrinology, 2007 - Endocrine Soc Immune modulators can arrest loss of insulin secretion in type 1 diabetes
mellitus (T1DM), but they have not caused permanent disease remission or
restored normal insulin secretion. We tested whether exendin-4, a ... Cited by 24 - Related articles - BL Direct - All 5 versions
N Soltani, M Kumar, Y Glinka, GJ Prud' … - Gene Therapy, 2007 - nature.com Glucagon-like peptide 1 (GLP-1) and its analogue exendin-4 (Ex4) have displayed
potent glucose homeostasis-modulating characteristics in type 2 diabetes (T2D).
However, there are few reports of effectiveness in type 1 diabetes (T1D) ... Cited by 18 - Related articles - BL Direct - All 4 versions
SL Samson, EV Gonzalez, V Yechoor, M Bajaj … - Molecular therapy: the journal of the American Society …, 2008 - pubmedcentral.nih.gov Exendin 4 (Ex4) is a glucagon-like peptide-1 receptor (GLP- 1R) agonist which is
available as a short-acting injectable treatment for type 2 diabetes. Our aim
was to characterize the long-term effects of elevated steady-state levels ... Cited by 1 - Related articles - All 5 versions
S Xue, CH Wasserfall, M Parker, TM Brusko, … - System, 1927 - interscience.wiley.com Recent studies, albeit controversial, have suggested that the incretin exendin-4
(Ex-4) is capable of inducing β cell proliferation in vivo. Furthermore, this
compound has been shown to enhance the ability of other agents (eg, ... Cited by 1 - Related articles - All 4 versions